Bone Biologics Corporation (BBLG) News
Follow Bone Biologics Corporation (BBLG) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
BBLG Reports Fiscal Q3 Net Loss
BBLG reported fiscal 2026 third-quarter net loss attributable to shareholders of -215.7万美元, up 11.01% year over year. Basic EPS was -0.88美元.
EQUITY | Oct 27, 2026, 04:49 AM UTC
M
Bone Biologics Reports Third-Quarter 2026 Net Loss of $618,000
Bone Biologics reported a net loss of $618,000 and diluted loss per share of $0.17 for the third quarter of 2026, compared with a $667,000 loss a year earlier.
EQUITY | Oct 26, 2026, 09:11 PM UTC
L
Bone Biologics adds three trial sites; enrollment expected by year-end 2026
Bone Biologics says it has added three trial sites, strengthening expectations to complete enrollment by year-end 2026.
EQUITY | Sep 08, 2026, 12:37 PM UTC
L
Bone Biologics to participate in H.C. Wainwright 28th Global Investment Conference
Bone Biologics Corporation (NASDAQ: BBLG, BBLGW) said it will participate in the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 03, 2026, 12:37 PM UTC
M
Healthcare Stocks Move
Gainers Catheter Precision (AMEX: VTAK ) shares rose 78.2% to $1.55 during Monday's after-market session. The company's market cap stands at $2.2 million. Allarity Therapeutics (NASDAQ: ALLR ) stock increased by 8.08% to
EQUITY | Jun 22, 2026, 09:10 PM UTC